Le Lézard
Classified in: Health, Science and technology

World Microbiome Adoption Research and Development Report 2021: Funding and Investment Analysis, Digital Technologies, Omics Platforms, Synthetic Biology, Culturing Technologies - ResearchAndMarkets.com


The "Technology Enablers Facilitating Microbiome Adoption in Research and Development" report has been added to ResearchAndMarkets.com's offering.

This research service provides an overview of technologies enabling microbiome research. Technology enablers address challenges in microbiome data collection and analysis, product development, and manufacturing.

Academic and research institutes, public and private organizations, and companies collaborate to develop and use integrated omics technologies, machine learning and artificial intelligence tools, microbial engineering through synthetic biology, and robust data analysis tools to manage vast amounts of microbiome data.

Knights Lab, Metabiomics, and Eagle Genomics are examples of companies offering machine learning and data analysis tools to facilitate microbiome research. Pacific Biosciences, MacCoss Lab of the University of Washington, and IsoPlexis are advancing omics technologies to improve microbiome research and address its challenges.

The study highlights notable funding and investment trends facilitating microbiome research globally. The United States leads the funding landscape as many public and private institutions support microbiome research and adoption, resulting in increased industry-academia partnerships.

Microbiome research is on the rise following technological advancements and significant cost reductions in microbiome analysis. Research has unlocked the potential of the microbiome in medical use cases, yielding tremendous insights on its nature, interactions, and impact within a host and in an external environment.

Advanced studies on the role of microbiota and their interactions with the host have enabled the development of innovative treatment strategies and diagnostic techniques. Research is also underway to explore microbiome applications in non-medical industries, such as agriculture, waste treatment, landfills, and marine.

Enabling technologies, namely digital technologies, omics, synthetic biology, and microbial culturing technologies, enhance microbiome research and development (R&D), manufacturing, product development, and commercialization. Advancements in digital technologies, such as big data analytics, machine learning, and artificial intelligence, contribute to collecting, synthesizing, and analyzing microbiome data for various applications.

Omics technologies such as genomics, transcriptomics, proteomics, and metabolomics improve the characterization of microbiome data, host-microbiome interactions, microbial response to external stimuli, deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) sequencing, and proteomics and metabolome profiles. Synthetic biology facilitates the design of engineered microbes for therapeutics, cell-based biosensors for diagnostics, and complex switches and synthetic gene networks for drug discovery.

Similarly, technological developments in high-throughput culturing techniques enable the culturing of previously uncultivable microorganisms. These technology enablers open up new opportunities and applications for microbiome-based products in industries.

The study also identifies growth opportunities for companies in the microbiome value chain and covers the following key areas:

Key Topics Covered:

1. Strategic Imperatives

1.1 Why Is It Increasingly Difficult to Grow? The Strategic Imperative 8: Factors Creating Pressure on Growth

1.2 The Strategic Imperative

1.3 The Impact of the Top Three Strategic Imperatives on Technology Enablers for Microbiome Applications

1.4 Growth Opportunities Fuel the Growth Pipeline Engine

2. Research Scope

2.1 Research Scope and Key Questions Addressed

2.2 Research Methodology

3. Growth Environment Analysis

3.1 Introduction to Microbiome Technologies

3.2 Role of Microbiome in Human Health

3.3 Role of Microbiome Across Multiple Disease Indications

3.4 Development of Microbiome-based Products

3.5 Key Bottlenecks in Microbiome R&D and Product Development

3.6 Need for Technology Enablers in Microbiome R&D and Product Development

4. Enabling Technology - Digital Technologies

4.1 Role of Digital Technologies in Microbiome R&D and Product Development

4.2 Data Analytics and ML Tools to Overcome R&D Bottlenecks

4.3 Academic and Research Institutes Develop Digital Tools for Microbiome Research

4.4 Digital Innovations Facilitate Microbiome Research

5. Enabling Technology - Omics Platforms

5.1 Role of Omics in Microbiome R&D and Product Development

5.2 Omics Technologies Facilitate Microbiome Research

5.3 Academic and Research Institutes Advanced Omics Platforms for Microbiome Analysis

5.4 Key Stakeholders Develop Omics Platforms for Microbiome R&D

5.5 Companies Keen to Use Omics Platforms for Product Development

6. Enabling Technology - Synthetic Biology

6.1 Role of Synthetic Biology in Microbiome R&D and Product Development

6.2 Synthetic Biology Has Increasing Applications in Microbiome Therapeutics and Diagnostics

6.3 Academic and Research Institutes Focus on Microbial Engineering

6.4 Research Institutes Explore the Potential of Microbiome in Non-medical Applications

6.5 Synthetic Biology Innovations Enable Microbial Engineering

7. Enabling Technology - Culturing Technologies

7.1 Role of Culturing Technologies in Microbiome R&D and Product Development

7.2 Innovations in Culturing Techniques Reduce R&D Lead Time

7.3 Academic Institutes Optimize Microbial Culturing Techniques

7.4 Innovations to Culture Uncultivable Microbes

8. Funding and Investment Analysis

8.1 Rising Investments and Research Grants for Microbiome Research

8.2 Federal Funding Bolsters Microbiome Research

8.3 Ongoing Trends in Microbiome Investments

8.4 Mergers, Acquisitions, and Collaborations Set to Increase Microbiome-based Products Commercialization

9. Growth Opportunity Universe

9.1 Growth Opportunity 1: Develop Advanced Data Analytics Tools for Effective Microbiome R&D and Product Development

9.2 Growth Opportunity 2: Standardize and Create Reference Materials to Advance Microbiome Research

9.3 Growth Opportunity 3: Synthetic Biology Techniques to Accelerate Large-scale Production of Engineered Strains

10. Next Steps

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/fwb8xw


These press releases may also interest you

at 19:18
Franchise Global Health Inc. ("Franchise Global" or the "Company")  (FRA: WV4A) is pleased to announce its results for the first quarter of 2022. "The Company's German reportable segment experienced strong sales and gross profit through the first...

at 19:06
Delfi Diagnostics, a pioneering developer of a new class of high-performance, affordable liquid biopsy tests for early cancer detection, will present updates at the 2022 annual meeting of the American Society for Clinical Oncology (ASCO) in Chicago...

at 19:05
St. Croix Hospice is proud to have earned four Gold and three Silver Aster Awards in the Home Health/Hospice group for marketing and communications materials created in 2021. The Aster Awards by Creative Images honor "excellence in healthcare...

at 18:59
Brookdale Senior Living Inc. ("Brookdale" or the "Company") announced today that Lucinda "Cindy" Baier, President and Chief Executive Officer will participate in the Jefferies Healthcare Conference Thursday, June 9, 2022. ...

at 18:36
Today, the Public Health Agency of Canada (PHAC) is confirming additional cases of monkeypox in Canada. In addition to the previously reported sixteen confirmed cases in Quebec, PHAC's National Microbiology Laboratory (NML) has confirmed another 10...

at 18:28
Cantargia (Cantargia AB) today reported extended interim results in first-line pancreatic cancer (PDAC) patients treated with nadunolimab (CAN04) in combination with gemcitabine and nab-paclitaxel in the phase I/IIa CANFOUR trial. The efficacy was...



News published on 20 january 2022 at 06:55 and distributed by: